Benjamin A. Sherer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Benjamin A. Sherer has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Alexander K. Chow
Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USA
1 shared publication - Anatoly Dritschilo
Department of Radiation Medicine, Georgetown University Hospital, 3800 Reservoir Road, NW, Washington, DC 20007, USA
1 shared publication - Andrew Wenhua Ju
Vidant Medical Center, East Carolina University
1 shared publication - Arjun V Pendharkar
Department of Urology, Georgetown University Hospital, Washington, DC, USA
1 shared publication Christopher L. Coogan
Department of Urology, Rush University Medical Center, Chicago, IL
1 shared publication- Christopher L. Coogan
Rush University Medical Center, Chicago, IL
1 shared publication
Latest Publications
- 7 October 2014
- Published by Springer Nature in Current Urology Reports
- Vol. 15 (12) , 1-7
2013-2014 Updates in Peyronie’s Disease Management
The number of patients presenting with Peyronie’s disease (PD) appears to be on the rise. This review provides an analysis of pertinent recent updates in the management of PD, focusing on data published within the past year. Objective benefit from injectable agents has been reported for years in mostly noncontrolled trials. The safety and efficacy of injectable collagenase clostridium histolyticum is now supported by data from a large-scale phase III randomized controlled trial. Other important advances have also been made in the surgical management of Peyronie’s disease, including new modifications to proven surgical techniques and a variety of approaches that can help enhance and restore penile length.
- 7 October 2014
- Published by Springer Nature in Current Urology Reports
- Vol. 15 (12) , 1-7
2013-2014 Updates in Peyronie’s Disease Management
The number of patients presenting with Peyronie’s disease (PD) appears to be on the rise. This review provides an analysis of pertinent recent updates in the management of PD, focusing on data published within the past year. Objective benefit from injectable agents has been reported for years in mostly noncontrolled trials. The safety and efficacy of injectable collagenase clostridium histolyticum is now supported by data from a large-scale phase III randomized controlled trial. Other important advances have also been made in the surgical management of Peyronie’s disease, including new modifications to proven surgical techniques and a variety of approaches that can help enhance and restore penile length.
- Open Access
- 31 January 2013
- Published by Springer Nature in Radiation Oncology
- Vol. 8 (1) , 30
Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer
Background: Hypofractionated stereotactic body radiation therapy (SBRT) has been advanced as monotherapy for low-risk prostate cancer. We examined the dose distributions and early clinical outcomes using this modality for the treatment of intermediate-risk prostate cancer. Methods: Forty-one sequential hormone-naïve intermediate-risk prostate cancer patients received 35–36.25 Gy of CyberKnife-delivered SBRT in 5 fractions. Radiation dose distributions were analyzed for coverage of potential microscopic ECE by measuring the distance from the prostatic capsule to the 33 Gy isodose line. PSA levels, toxicities, and quality of life (QOL) measures were assessed at baseline and follow-up. Results: All patients completed treatment with a mean coverage by the 33 Gy isodose line extending >5 mm beyond the prostatic capsule in all directions except posteriorly. Clinical responses were documented by a mean PSA decrease from 7.67 ng/mL pretreatment to 0.64 ng/mL at the median follow-up of 21 months. Forty patients remain free from biochemical progression. No Grade 3 or 4 toxicities were observed. Mean EPIC urinary irritation/obstruction and bowel QOL scores exhibited a transient decline post-treatment with a subsequent return to baseline. No significant change in sexual QOL was observed. Conclusions: In this intermediate-risk patient population, an adequate radiation dose was delivered to areas of expected microscopic ECE in the majority of patients. Although prospective studies are needed to confirm long-term tumor control and toxicity, the short-term PSA response, biochemical relapse-free survival rate, and QOL in this interim analysis are comparable to results reported for prostate brachytherapy or external beam radiotherapy. Trial registration: The Georgetown Institutional Review Board has approved this retrospective study (IRB 2009–510).
- 31 January 2013
- Published by Springer Nature in Radiation Oncology
- Vol. 8 (1) , 30
Open AccessHypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer
Background: Hypofractionated stereotactic body radiation therapy (SBRT) has been advanced as monotherapy for low-risk prostate cancer. We examined the dose distributions and early clinical outcomes using this modality for the treatment of intermediate-risk prostate cancer. Methods: Forty-one sequential hormone-naïve intermediate-risk prostate cancer patients received 35–36.25 Gy of CyberKnife-delivered SBRT in 5 fractions. Radiation dose distributions were analyzed for coverage of potential microscopic ECE by measuring the distance from the prostatic capsule to the 33 Gy isodose line. PSA levels, toxicities, and quality of life (QOL) measures were assessed at baseline and follow-up. Results: All patients completed treatment with a mean coverage by the 33 Gy isodose line extending >5 mm beyond the prostatic capsule in all directions except posteriorly. Clinical responses were documented by a mean PSA decrease from 7.67 ng/mL pretreatment to 0.64 ng/mL at the median follow-up of 21 months. Forty patients remain free from biochemical progression. No Grade 3 or 4 toxicities were observed. Mean EPIC urinary irritation/obstruction and bowel QOL scores exhibited a transient decline post-treatment with a subsequent return to baseline. No significant change in sexual QOL was observed. Conclusions: In this intermediate-risk patient population, an adequate radiation dose was delivered to areas of expected microscopic ECE in the majority of patients. Although prospective studies are needed to confirm long-term tumor control and toxicity, the short-term PSA response, biochemical relapse-free survival rate, and QOL in this interim analysis are comparable to results reported for prostate brachytherapy or external beam radiotherapy. Trial registration: The Georgetown Institutional Review Board has approved this retrospective study (IRB 2009–510).